Trial Profile
Effectiveness and safety of Combination therapy of Ranibizumab and LuseOgliflozin in type 2 diabetes with diabetic Macular Edema, a parallel group comparison with the standard Treatment controlled by Glimepiride, multicenter, randomized, open-label trial. (COMET Trial)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Luseogliflozin (Primary) ; Ranibizumab (Primary) ; Glimepiride
- Indications Diabetic macular oedema; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms COMET Trial
- 02 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 01 Jan 2020 Trial design (Protocol) of COMET trial has been published in the Diabetes Therapy.
- 04 Mar 2019 Status changed from not yet recruiting to recruiting.